## FORM 4

Check this box if no longer subject

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
wasiiiigton,	D.C.	20349

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

1. Name and Address of Reporting Person* <u>LILLY ENDOWMENT INC</u>				Section 30(f) of the investment Company Act of 1940      Issuer Name and Ticker or Trading Symbol     ELI LILLY & Co [ LLY ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director				
(Last) (First) (Middle) 2801 NORTH MERIDIAN STREET					3. Date of Earliest Transaction (Month/Day/Year) 06/16/2020								Office below	r (give title r)	Other (specify below)	
(Street) INDIANAPOLIS IN 46208-0068			4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	•				
(City)	(St		Zip)													
			I - Non-Deriva				<u> </u>	red,	· ·				1			<b>-</b>
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	er) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	(Instr. 4)
Common	Stock		06/16/2020				S		2,909	D	\$158	3.5379 <sup>(1)</sup>	112,	194,732	D	
Common	Stock		06/16/2020				S		18,466	D	\$159	.5698 <sup>(2)</sup>	112,	176,266	D	
Common Stock 06/16/2020					S		17,850	D	\$160	\$160.3544 <sup>(3)</sup>		158,416	D			
Common Stock 06/16/2020					S		19,290	D	\$16	\$161.456 <sup>(4)</sup>		139,126	D			
Common Stock 06/		06/16/2020	)		S		46,024	D	\$16	\$162.655 <sup>(5)</sup>		112,093,102 I				
Common Stock 06/16/20		06/16/2020			S		56,144	D	\$16	\$163.402 <sup>(6)</sup>		036,958	D			
Common Stock		06/16/2020	0			S		19,373	D	D \$164.57		(7) 112,017,585		D		
Common Stock		06/16/2020	0		S			15,935	D	\$16	\$165.601 <sup>(8)</sup>		001,650	D		
Common Stock		06/16/2020	0		S			14,823	D	\$16	\$166.414 <sup>(9)</sup>		986,827	D		
Common Stock 06/16/2020		,		S		1,523	D	\$167	\$167.179(10)		985,304	D				
		Та	ble II - Derivati										Owned	d I		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans	Transaction of Code (Instr. Derivate		6. Date E Expiration (Month/II)		xercisable a	nd 7. Ai Se Ui De Se			Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
				Code	v	(A) (		ate kercisa	Expirate Date	tion Ti	or Nur of	nber res				

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$158.00 to \$158.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$159.00 to \$159.99, inclusive.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$160.00 to \$160.98, inclusive.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$161.00 to \$161.99, inclusive. 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$162.02 to \$163.01, inclusive.
- 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$163.02 to \$164.00, inclusive.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$164.02 to \$165.00, inclusive.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$165.02 to \$166.01, inclusive.
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$166.02 to \$166.99, inclusive.
- 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$167.05 to \$167.27, inclusive.

### Remarks:

/s/Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment

06/17/2020

Inc.

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.